Contact Us Careers
English 简体中文 繁體中文
EN 中文 繁體

肝胆胰癌

"Anti-cancer Special Force vNKT" is emerging as a rising star in China's immunology community.

Lung Cancer Stomach Cancer Hepatobiliary and Pancreatic Cancers Intestine Cancer Breast Cancer B-cell lymphoma Cervical Cancer Other Solid Tumors
Home > Oncology Clinical Research > 肝胆胰癌

肝胆胰癌

The patient had two recurrences one year after liver cancer surgery, but has now been stable for over seven years

Mr. Yan's quality of life has been greatly improved. He is in excellent mental condition, feels more energetic when doing... ...
View More+

How can one manage to survive for 7 years with dual primary tumors in the liver and lung?

Mr. Wang, however, achieved long-term stability under the combined treatment of CyberKnife and NKT cells, and as of March... ...
View More+

Adding this adjuvant therapy after surgery for cholangiocellular carcinoma can improve prognosis

After adopting NKT cell therapy, Ms. Zhang achieved the expected results. Over a year has passed since the last evaluatio... ...
View More+

Pancreatic cancer has a high recurrence rate and poor prognosis, and combined cell therapy can improve survival

Mr. Li achieved the expected effect after adopting the vNKT cell therapy method, and the current follow-up assessment res... ...
View More+

Low survival rate cholangiocarcinoma: about to break through the five-year cure threshold!

The 5-year survival rate for cholangiocellular carcinoma ranges from 20% to 35%. With comprehensive treatment plus vNKT c... ...
View More+

Nine rounds of vNKT cell reinfusion have significantly enhanced immunity, freeing patients from the worry of liver cancer recurrence

Immune escape mechanisms lead to recurrence of liver cancer. Through the infusion of vNKT cells, immune balance is restor... ...
View More+

Liver cancer with cirrhosis: Breaking the ice of low survival rate, with no recurrence or metastasis in 5 years after cell therapy

Mr. Ma has actively undergone vNKT cell therapy and has been in a stable condition for 5 years, achieving the expected th... ...
View More+

Is the recurrence rate of liver cancer extremely high? Immunotherapy helps achieve 9 years without recurrence

After comprehensive comparison with multiple parties, Mr. Yan chose vNKT cell therapy and has been living a stable life f... ...
View More+

Out of 10 cases of liver cancer, 7 have recurred. Small liver cancers should not be taken lightly either!

After experiencing a second relapse, Mr. Feng actively sought post-operative adjuvant therapy options and chose vNKT cell... ...
View More+

How can this high-risk cancer, which is prone to delayed diagnosis and recurrence, achieve a 9-year relapse-free period?

After scientific analysis and comparison, Mr. Wang chose vNKT cell therapy, and his condition has remained stable for 9 y... ...
View More+
About Lehe
Corporate Culture Founder's Introduction Lehe News Story of Lehe Science Popularization Academic Literature
New Medical Services
Second Consultation Rehabilitation and Wellness Elite Care
Oncology Clinical Research
Lung Cancer Stomach Cancer Hepatobiliary and Pancreatic Cancers Intestine Cancer Breast Cancer B-cell lymphoma Cervical Cancer Other Solid Tumors
Chronic Disease Research
Hypertension Diabetes Obesity Immune Diseases Degenerative Diseases Chronic Inflammation Others

Contact Us

Address: Room 1101 (Unit 101), 11th Floor, Building 1, No. 7 Courtyard, Kexueyuan Road, Life Science Park, Changping District, Beijing
Phone：010-8265 9866
Email：lehemedneo@hotmail.com

微信
抖音
哔哩哔哩
头条
Copyright©2022 Beijing Lehe New Medical Clinic Co., Ltd. All Rights Reserved ICP: 京ICP备2025148232号 京公网安备11011402054997号 Privacy Policy